D.A. Davidson & CO. Increases Stock Position in Zoetis Inc. (NYSE:ZTS)

D.A. Davidson & CO. grew its position in shares of Zoetis Inc. (NYSE:ZTS) by 7.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,794 shares of the company’s stock after purchasing an additional 1,567 shares during the period. D.A. Davidson & CO.’s holdings in Zoetis were worth $4,302,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in ZTS. Sachetta LLC purchased a new stake in shares of Zoetis during the 4th quarter valued at about $368,000. Wells Fargo & Company MN boosted its holdings in shares of Zoetis by 1.2% in the 4th quarter. Wells Fargo & Company MN now owns 2,595,972 shares of the company’s stock worth $512,367,000 after purchasing an additional 29,923 shares during the period. Balentine LLC increased its position in shares of Zoetis by 36.8% during the 4th quarter. Balentine LLC now owns 6,713 shares of the company’s stock valued at $1,325,000 after purchasing an additional 1,806 shares during the last quarter. Associated Banc Corp raised its holdings in Zoetis by 3.2% during the 4th quarter. Associated Banc Corp now owns 50,059 shares of the company’s stock valued at $9,880,000 after buying an additional 1,534 shares during the period. Finally, Coldstream Capital Management Inc. lifted its position in Zoetis by 21.0% in the fourth quarter. Coldstream Capital Management Inc. now owns 8,952 shares of the company’s stock worth $1,767,000 after buying an additional 1,554 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 0.4 %

Shares of NYSE ZTS opened at $172.05 on Thursday. The stock has a fifty day simple moving average of $164.22 and a 200-day simple moving average of $179.63. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a current ratio of 3.33, a quick ratio of 1.94 and a debt-to-equity ratio of 1.30. The stock has a market capitalization of $78.51 billion, a PE ratio of 33.15, a PEG ratio of 2.68 and a beta of 0.86.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The firm had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. During the same period in the prior year, the firm earned $1.31 earnings per share. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. On average, equities analysts forecast that Zoetis Inc. will post 5.77 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the completion of the sale, the executive vice president now directly owns 14,800 shares of the company’s stock, valued at $2,237,316. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. HSBC dropped their price target on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Barclays cut their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. The Goldman Sachs Group decreased their price target on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research note on Monday, May 6th. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Finally, Stifel Nicolaus decreased their target price on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $211.75.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.